EyePoint, Inc. - Common Stock (NQ:EYPT)

3.320 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews ↗

March 06, 2025

Via Benzinga

Earnings Scheduled For March 5, 2025 ↗

March 05, 2025

Via Benzinga

Analyst Ratings For EyePoint Pharmaceuticals ↗

October 25, 2024

Via Benzinga

EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

August 13, 2024

Via Benzinga

Deep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings) ↗

May 07, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

February 05, 2025

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 28, 2024

Via Benzinga

Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know ↗

March 08, 2024

Via Benzinga

A Preview Of EyePoint Pharmaceuticals's Earnings ↗

March 06, 2024

Via Benzinga

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss ↗

October 28, 2024

EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.

Via Benzinga

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

October 28, 2024

Via Benzinga

NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday ↗

October 14, 2024

Via Benzinga

Topics Government

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 12, 2024

Via Benzinga

Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday ↗

July 12, 2024

Via Benzinga

Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 13, 2024

Via Benzinga

EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

EYPT stock results show that EyePoint Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

May 08, 2024

Via Benzinga

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge ↗

May 06, 2024

Via Benzinga

Topics Stocks

Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday ↗

May 06, 2024

Via Benzinga

Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results ↗

May 06, 2024

Via Benzinga

Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session ↗

May 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 06, 2024

Via Benzinga

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views ↗

May 06, 2024

Via Benzinga

Topics Earnings

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? ↗

May 06, 2024

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 06, 2024

Via Benzinga

Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

April 23, 2024

Via Benzinga

EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 ↗

March 07, 2024

EYPT stock results show that EyePoint Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.